Hyperbaric Oxygen Therapy (HBOT) for Alzheimer's Disease

Also known as: HBOT, HBO, Hyperbaric medicine

HBOT increases brain oxygen tension, potentially reversing hypoxia-driven amyloid production and improving cerebrovascular function.

Mechanism of Action

HBOT increases dissolved plasma oxygen, enhancing tissue oxygenation beyond hemoglobin capacity. It mobilizes stem cells, promotes angiogenesis, reduces neuroinflammation, and activates HIF-1α target genes during intermittent hyperoxia/normoxia cycling. May clear amyloid through improved oxygenation.

General mechanism: Pressurized oxygen delivery. Hyperoxia/normoxia cycling activates HIF pathway, stem cell mobilization, angiogenesis, anti-inflammatory signaling.

Current Evidence

Tel Aviv University study showed HBOT improved cognitive function and brain perfusion in elderly adults. Amyloid PET changes documented. Phase II trials for AD specifically are ongoing.

Clinical Status: Phase II trials for cognitive decline. Positive results in aging studies.

Safety Profile

Generally safe. Ear/sinus barotrauma, oxygen toxicity seizures (rare). Contraindicated with untreated pneumothorax. Specialized facility required.

Key Research Questions

View glossary entry →

← Back to Alzheimer's Disease Research